Summary and Concluding Remarks
RDN using the Symplicity RDN system represents an exciting and innovative development in the eld of interventional medicine. It has demonstrated signicant and sustained reductions in BP in the Symplicity HTN-1 and Symplicity HTN-2 clinical trials. The Global SYMPLICITY Registry has also demonstrated safety and effectiveness in real-world clinical practice in the subjects for which data are available. New systems containing multi-electrodes has the potential to make RDN as easy and straightforward as the existing single-electrode catheter while reducing ablation time. Furthermore, the benets of RDN may not be restricted to blood pressure lowering alone; the potential exists to expand its therapeutic indications. However, RDN is a relatively new technique and optimal patient selection is crucial. The joint expertise of different elds is required to identify patients who have truly resistant hypertension and are likely to respond to RDN. Clinical evidence to date suggests that a high baseline SBP is the best predictor of response. In conclusion, RDN is currently an effective and safe option if used in well-selected patients. As more clinical data become available, the approach to RDN is likely to become more accessible with an increase in indications.